Low-dose spironolactone attenuates metabolic defects in the skeletal muscle of letrozole-induced hyperandrogenic female rats

[1]  O. Adeyanju,et al.  Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. , 2020, Toxicology and applied pharmacology.

[2]  K. Olaniyi,et al.  L-glutamine ameliorates adipose-hepatic dysmetabolism in OC-treated female rats. , 2020, The Journal of endocrinology.

[3]  Mingqing Huang,et al.  Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[4]  E. Stener-Victorin,et al.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome , 2020, Endocrine reviews.

[5]  O. Michael,et al.  Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid—a familiar foe , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  R. Ebrahimi,et al.  Acetylation and insulin resistance: a focus on metabolic and mitogenic cascades of insulin signaling , 2020, Critical reviews in clinical laboratory sciences.

[7]  O. Adeyanju,et al.  Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone. , 2019, Chemico-biological interactions.

[8]  U. Zafar,et al.  Prevalence of PCOS with Associated Symptoms and Complications at Tertiary Care Hospital of Karachi , 2019, Journal of Advances in Medicine and Medical Research.

[9]  K. Olaniyi,et al.  Inhibition of pyruvate dehydrogenase kinase-4 by l-glutamine protects pregnant rats against fructose-induced obesity and hepatic lipid accumulation. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  C. Lee,et al.  Therapeutic Effect of Ecklonia cava Extract in Letrozole-Induced Polycystic Ovary Syndrome Rats , 2018, Front. Pharmacol..

[11]  O. Michael,et al.  Blockade of mineralocorticoid receptor ameliorates oral contraceptive-induced insulin resistance by suppressing elevated uric acid and glycogen synthase kinase-3 instead of circulating mineralocorticoid , 2018, Archives of physiology and biochemistry.

[12]  L. Redman,et al.  Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome†‡ , 2018, Human reproduction.

[13]  A. Díaz-Villaseñor,et al.  Adiponectin synthesis and secretion by subcutaneous adipose tissue is impaired during obesity by endoplasmic reticulum stress , 2018, Journal of cellular biochemistry.

[14]  S. Alwasel,et al.  Body fat affects mouse reproduction, ovarian hormone release, and response to follicular stimulating hormone. , 2017, Reproductive biology.

[15]  M. Hedayati,et al.  The Effects of Exercise on Expression of CYP19 and StAR mRNA in Steroid-Induced Polycystic Ovaries of Female Rats , 2017, International journal of fertility & sterility.

[16]  K. Parivar,et al.  Effect of Grape Seed Extract on Lipid Profile and Expression of Interleukin-6 in Polycystic Ovarian Syndrome Wistar Rat Model , 2017, International journal of fertility & sterility.

[17]  L. Chow,et al.  Effect of acute physiological free fatty acid elevation in the context of hyperinsulinemia on fiber type-specific IMCL accumulation. , 2017, Journal of applied physiology.

[18]  Xia Zhao,et al.  Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy , 2017, Experimental and therapeutic medicine.

[19]  G. Delitala,et al.  Polycystic ovary syndrome, adipose tissue and metabolic syndrome , 2017, Archives of Gynecology and Obstetrics.

[20]  C. Reisenauer.  Presentation and management of vesicovaginal fistulae after delivery at a German women’s hospital , 2017, Archives of Gynecology and Obstetrics.

[21]  S. Reeves,et al.  Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges , 2017, Nutrition Research Reviews.

[22]  M. Ehrlich,et al.  Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels , 2016, Alzheimer's & Dementia.

[23]  D. Armanini,et al.  Spironolactone in the treatment of polycystic ovary syndrome , 2016, Expert opinion on pharmacotherapy.

[24]  L. Lenghel,et al.  Letrozole vs estradiol valerate induced PCOS in rats: glycemic, oxidative and inflammatory status assessment. , 2016, Reproduction.

[25]  N. Webster,et al.  A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice1 , 2015, Biology of reproduction.

[26]  B. Faubert,et al.  Resveratrol prevents insulin resistance caused by short-term elevation of free fatty acids in vivo. , 2015, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[27]  F. Zullo,et al.  Polycystic ovary syndrome: chemical pharmacotherapy , 2015, Expert opinion on pharmacotherapy.

[28]  S. Zoungas,et al.  Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. , 2015, Journal of women's health.

[29]  S. Kjaer,et al.  Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. , 2015, Gynecologic oncology.

[30]  A. Majumdar,et al.  Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats , 2014, The Journal of pharmacy and pharmacology.

[31]  E. Stener-Victorin,et al.  Rodent Models of Polycystic Ovary Syndrome: Phenotypic Presentation, Pathophysiology, and the Effects of Different Interventions , 2014, Seminars in Reproductive Medicine.

[32]  A. Mureşan,et al.  Spironolactone and dimethylsulfoxide effect on glucose metabolism and oxidative stress markers in polycystic ovarian syndrome rat model. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[33]  S. Nisar,et al.  Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. , 2013, The Journal of clinical endocrinology and metabolism.

[34]  Richard S. Legro,et al.  Longterm management of Polycystic Ovarian Syndrome (PCOS) , 2013, Molecular and Cellular Endocrinology.

[35]  S. Menon,et al.  Anti-androgenic effect of Symplocos racemosa Roxb. against letrozole induced polycystic ovary using rat model , 2013 .

[36]  Gerald,et al.  31 P Nuclear Magnetic Resonance Measurements of Muscle Glucose-6-Phosphate Evidence for Reduced Insulin-dependent Muscle Glucose Transport or Phosphorylation Activity in Non-Insulin-dependent Diabetes Mellitus , 2013 .

[37]  E. Diamanti-Kandarakis,et al.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. , 2012, Endocrine reviews.

[38]  M. Ganie,et al.  Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[39]  Jimmy D Bell,et al.  Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. , 2012, The Journal of clinical endocrinology and metabolism.

[40]  L. Mannerås-Holm,et al.  Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial. , 2012, Fertility and sterility.

[41]  D. Calhoun,et al.  Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics , 2011, Journal of clinical hypertension.

[42]  W. Blaner,et al.  DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle[S] , 2011, Journal of Lipid Research.

[43]  Ricardo Azziz,et al.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis , 2011, Nature Reviews Endocrinology.

[44]  J. Preželj,et al.  Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. , 2011, European journal of endocrinology.

[45]  S. Groth.  Adiponectin and Polycystic Ovary Syndrome , 2010, Biological research for nursing.

[46]  M. Peppa,et al.  Skeletal Muscle Insulin Resistance in Endocrine Disease , 2010, Journal of biomedicine & biotechnology.

[47]  S. Kihara,et al.  Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. , 2009, Cardiovascular research.

[48]  Wei Hu,et al.  Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity[S] , 2009, Journal of Lipid Research.

[49]  Wei Zhang,et al.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. , 2009, The Journal of clinical investigation.

[50]  R. Norman,et al.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.

[51]  R. Coleman,et al.  Hepatic triacylglycerol accumulation and insulin resistance , 2009 .

[52]  R. Eckel,et al.  Skeletal Muscle–Specific Deletion of Lipoprotein Lipase Enhances Insulin Signaling in Skeletal Muscle but Causes Insulin Resistance in Liver and Other Tissues , 2008, Diabetes.

[53]  R. Curi,et al.  Updating the effects of fatty acids on skeletal muscle , 2008, Journal of cellular physiology.

[54]  J. Shaw,et al.  Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. , 2008, Human reproduction.

[55]  K. Sakamoto,et al.  Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. , 2008, American journal of physiology. Endocrinology and metabolism.

[56]  G. Adler,et al.  Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-&ggr;, and Proinflammatory Adipokines , 2008, Circulation.

[57]  J. Sowers,et al.  Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. , 2008, American journal of physiology. Endocrinology and metabolism.

[58]  K. Sakamoto,et al.  Emerging role for AS 160 / TBC 1 D 4 and TBC 1 D 1 in the regulation of GLUT 4 traffic , 2008 .

[59]  C. Fiore,et al.  Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. , 2007, Hypertension.

[60]  G. Ramponi,et al.  Integrin-mediated cell adhesion and spreading engage different sources of reactive oxygen species. , 2007, Antioxidants & redox signaling.

[61]  M. Urbanek.  The genetics of the polycystic ovary syndrome , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[62]  J. Marshall,et al.  The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. , 2006, Human reproduction update.

[63]  D. Armanini,et al.  Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile , 2005, Journal of endocrinological investigation.

[64]  Joseph L Evans,et al.  The molecular basis for oxidative stress-induced insulin resistance. , 2005, Antioxidants & redox signaling.

[65]  D. Abbott,et al.  Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? , 2005, Human reproduction update.

[66]  S. Dwivedi,et al.  Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. , 2004, The Journal of clinical endocrinology and metabolism.

[67]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[68]  F. Keleştimur,et al.  A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. , 2004, European journal of endocrinology.

[69]  H. Kafalı,et al.  Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. , 2004, Archives of medical research.

[70]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[71]  Jie Deng,et al.  Insulin resistance and prostate cancer risk. , 2003, Journal of the National Cancer Institute.

[72]  Joseph L Evans,et al.  Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. , 2002, The Journal of clinical endocrinology and metabolism.

[73]  U. Pagotto,et al.  Obesity and the polycystic ovary syndrome , 2002, International Journal of Obesity.

[74]  D. Driscoll,et al.  Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. , 2002, The Journal of clinical endocrinology and metabolism.

[75]  J. Sastre,et al.  Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. , 2002, Diabetes.

[76]  Jiong Wu,et al.  Molecular Mechanism of Insulin-Induced Degradation of Insulin Receptor Substrate 1 , 2002, Molecular and Cellular Biology.

[77]  Julie Brown,et al.  Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. , 2009, The Cochrane database of systematic reviews.

[78]  L. Carpenter,et al.  A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. , 2001, Diabetes.

[79]  E. Diamanti-Kandarakis,et al.  Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). , 2001, American journal of physiology. Endocrinology and metabolism.

[80]  G. Dohm,et al.  Lipid oxidation is reduced in obese human skeletal muscle. , 2000, American journal of physiology. Endocrinology and metabolism.

[81]  P. Spritzer,et al.  Spironolactone as a single agent for long‐term therapy of hirsute patients , 2000, Clinical endocrinology.

[82]  A. Dunaif,et al.  Selective insulin resistance in the polycystic ovary syndrome. , 1999, The Journal of clinical endocrinology and metabolism.

[83]  G. Shulman,et al.  Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. , 1999, Diabetes.

[84]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[85]  E. Diamanti-Kandarakis,et al.  The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[86]  J. Marshall,et al.  Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. , 1998, The Journal of clinical endocrinology and metabolism.

[87]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[88]  A. Dunaif,et al.  Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. , 1995, The Journal of clinical investigation.

[89]  R. Reid,et al.  Polycystic ovaries are a common finding in untreated female to male transsexuals , 1993 .

[90]  M. Uchiyama,et al.  Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. , 1978, Analytical biochemistry.